(PBH) Prestige Brand Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74112D1019

PBH EPS (Earnings per Share)

This chart shows the EPS (Earnings per Share) of PBH over the last 5 years for every Quarter.

PBH Revenue

This chart shows the Revenue of PBH over the last 5 years for every Quarter.

PBH: Pain Relievers, Throat Sprays, Eye Drops, Skin Treatments, Digestive Aids

Prestige Consumer Healthcare Inc. (NYSE:PBH) is a leading developer, manufacturer, and distributor of over-the-counter (OTC) health and personal care products. The company operates through two primary segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio includes well-known brands such as BC, Goodys, Boudreauxs Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Fleet, Gaviscon, Ludens, Monistat, Nix, Summers Eve, TheraTears, Fess, and Hydralyte. These products address a wide range of healthcare needs, including pain relief, digestive health, feminine care, skincare, and oral rehydration. The company distributes its products through mass merchandisers, drugstores, food retailers, convenience stores, and e-commerce platforms. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. The company rebranded from Prestige Brands Holdings, Inc. to Prestige Consumer Healthcare Inc. in August 2018 to better reflect its focus on consumer health products.

The companys product lineup includes analgesic powders, diaper rash treatments, sore throat sprays, eye care products, wart removal solutions, ear wax removal products, dental care accessories, motion sickness remedies, laxatives, antacids, cough drops, yeast infection treatments, lice treatments, feminine hygiene products, dry eye remedies, nasal saline sprays, and oral rehydration solutions. This broad range of offerings positions Prestige Consumer Healthcare Inc. as a key player in the OTC healthcare market, catering to both domestic and international markets.

Based on the provided data, here is a 3-month forecast:

Technical Outlook: The stock is currently trading below its 20-day and 50-day moving averages (SMA20: 81.97, SMA50: 83.85) but remains above its 200-day moving average (SMA200: 77.41). This indicates potential short-term weakness but longer-term bullish momentum. The Average True Range (ATR) of 2.33 suggests moderate volatility, which could lead to price swings in the near term.

Fundamental Outlook: With a market cap of $4.068 billion and a price-to-earnings (P/E) ratio of 19.28, the stock is trading at a premium compared to its forward P/E of 16.98, suggesting expectations of future earnings growth. The price-to-book (P/B) ratio of 2.24 indicates that the stock may be overvalued relative to its book value. The price-to-sales (P/S) ratio of 3.64 reflects a higher valuation compared to its revenue. Return on equity (RoE) of 11.96% highlights decent profitability.

3-Month Forecast: Expect the stock to consolidate near current levels, with potential support at $77.41 (SMA200) and resistance at $83.85 (SMA50). Earnings reports and macroeconomic conditions will likely influence short-term movements. If the company meets or exceeds forward earnings expectations, the stock could rebound toward its SMA50 level. Conversely, any negative surprises could push it toward its SMA200 support.

Additional Sources for PBH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

PBH Stock Overview

Market Cap in USD 4,172m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2005-02-10

PBH Stock Ratings

Growth Rating 78.2
Fundamental 49.0
Dividend Rating 0.21
Rel. Strength 47
Analysts 3.71 of 5
Fair Price Momentum 92.48 USD
Fair Price DCF 105.62 USD

PBH Dividends

Currently no dividends paid

PBH Growth Ratios

Growth Correlation 3m -6.2%
Growth Correlation 12m 86.6%
Growth Correlation 5y 90.8%
CAGR 5y 15.22%
CAGR/Max DD 5y 0.59
Sharpe Ratio 12m 0.70
Alpha 27.63
Beta 0.344
Volatility 27.29%
Current Volume 341.4k
Average Volume 20d 382.2k
What is the price of PBH shares?
As of May 24, 2025, the stock is trading at USD 85.75 with a total of 341,432 shares traded.
Over the past week, the price has changed by -3.75%, over one month by +7.50%, over three months by +0.79% and over the past year by +34.34%.
Is Prestige Brand Holdings a good stock to buy?
Partly, yes. Based on ValueRay´s Fundamental Analyses, Prestige Brand Holdings (NYSE:PBH) is currently (May 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 49.00 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PBH is around 92.48 USD . This means that PBH is currently overvalued and has a potential downside of 7.85%.
Is PBH a buy, sell or hold?
Prestige Brand Holdings has received a consensus analysts rating of 3.71. Therefor, it is recommend to hold PBH.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 3
  • Sell: 1
  • Strong Sell: 0
What are the forecasts for PBH share price target?
According to our own proprietary Forecast Model, PBH Prestige Brand Holdings will be worth about 100.3 in May 2026. The stock is currently trading at 85.75. This means that the stock has a potential upside of +16.98%.
Issuer Target Up/Down from current
Wallstreet Target Price 88.5 3.2%
Analysts Target Price 88.5 3.2%
ValueRay Target Price 100.3 17%